Daré Bioscience, Inc. (NASDAQ:DARE) Sees Significant Growth in Short Interest

Daré Bioscience, Inc. (NASDAQ:DARE) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 86,600 shares, a growth of 50.9% from the December 15th total of 57,400 shares. Based on an average trading volume of 50,200 shares, the days-to-cover ratio is currently 1.7 days. Currently, 1.0% of the company’s shares are sold short.

Institutional Investors Weigh In On Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC grew its holdings in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the period. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 as of its most recent SEC filing. Institutional investors own 6.70% of the company’s stock.

Daré Bioscience Trading Up 0.3 %

Shares of DARE stock traded up $0.01 during midday trading on Friday, reaching $3.34. 11,893 shares of the stock were exchanged, compared to its average volume of 22,963. Daré Bioscience has a 1 year low of $2.67 and a 1 year high of $7.56. The firm has a market cap of $29.06 million, a PE ratio of -5.65 and a beta of 1.28. The company’s 50 day moving average is $3.30 and its two-hundred day moving average is $3.42.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Daré Bioscience in a research report on Tuesday, December 17th.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.